The Food and Drug Administration has said it's open to making a COVID-19 vaccine available before phase 3 clinical trials are complete.
Stephen Hahn, commissioner of the Food and Drug Administration, told the Financial Times last week that he was "prepared to authorize a vaccine before phase 3 clinical trials were complete, as long as officials believed the benefits outweighed the risks."
Typically, phase 1 trials involve a small number of volunteers.